Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00457249 · ClinicalTrials.gov registry record · Phase 4
A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,564
- Enrollment target
NCT00457249: Completed Phase 4 study, sponsored by Sanofi.
NCT00457249 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 1,564 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (202% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00457249, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,564 participants
- Enrollment target
Study Summary
It is well recognized that older adults can contract pertussis, suffer its complications, and unwittingly transmit it to close contacts, which may well include infants too young to have received their primary series of DTaP vaccinations. ADACEL® vaccine is currently licensed in the US for persons 11 - 64 years of age, but no pertussis vaccine is yet approved for administration to older adults. The most widely used Td vaccine in the US, DECAVAC®, has no upper limit on its age indication. The purpose of this trial is to describe the safety and immunogenicity of ADACEL® vaccine among individuals ≥ 65 years of age.
Interventions
- BIOLOGICAL ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed
- BIOLOGICAL DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,564 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-11 |
| Phase | Phase 4 |
What the finished NCT00457249 record still lists
NCT00457249 is an interventional study that assigns participants to a tested intervention. Its 1,564 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (202% higher).
The record links to 0 conditions, and to 2 interventions - of which ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed is the first listed.
NCT00457249 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00457249 about?
NCT00457249 is a clinical study titled "A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older". It is well recognized that older adults can contract pertussis, suffer its complications, and unwittingly transmit it to close contacts, which may well include infants too young to have received their primary series of DTaP vaccinations. ADACEL® vaccine is currently licensed in the US for persons 11...
What is the current status of trial NCT00457249?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,564 participants. The study started on 2007-03. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00457249?
The interventions under investigation include: ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed (BIOLOGICAL), DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed (BIOLOGICAL).
Who is sponsoring clinical trial NCT00457249?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00457249's enrollment target sits among peer trials
1,564 50th of 2000 higher than 1,951 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06034080 · 1,566 participants · NA
Interventions to De-implement Unnecessary Antibiotic Prescribing for Children With Ear Infections
- NCT06881069 · 1,560 participants · NA
Reach Through Equitable Implementation in Utah
- NCT06445946 · 1,572 participants · Phase 4
DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes
- NCT02650622 · 1,550 participants
Genetic and Metabolic Disease in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia